Uterine fibroids: Myomectomy is more cost-effective than uterine artery embolization

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.